Tianxing Medical (01609), as the absolute leader in domestic sports medicine, combines a high-growth track, strong profitability, and scarcity, making it a "small but beautiful" high-quality target for Hong Kong stock IPOs.
Industry Position: Domestic sports medicine market share is 6.5% (No. 1 among domestic players), second only to the three major foreign giants Stryker, Johnson & Johnson, and Smith & Nephew (combined share 59.3%).
Domestic Substitution Window: After the centralized procurement policy landed in May 2024, foreign players' share plummeted from 80% to 50%. The company, as the sole domestic leader, directly benefits.
High-Growth Track: The sports medicine market is expected to grow at a CAGR of 16.5% from 2024 to 2030; the smart rehabilitation track is expected to grow at 47.5%, reaching a scale of RMB 22.9 billion by 2030, which the company has already entered.
Product Portfolio: 62 products covering all major joints (shoulder/knee/hip/ankle), with 27 Class III and 25 Class II certifications, the most among domestic companies.
Technological Breakthroughs: Three core technologies (absorbable technology, all-suture technology, PPEK injection molding technology) break international monopolies, with 11 products being domestic firsts.
Hospital Coverage: Entered 3000+ hospitals (including 1000+ tertiary hospitals), with cumulative sales exceeding 2 million units, indicating high clinical recognition.
IPO Subscription Advantages: Small cap + Strong cornerstone investors
Small Market Cap: Issue price of HKD 98.5, total market cap of approximately HKD 5.4 billion, with a very small public float (public offering only 16,800 lots).
Luxury Cornerstone: Cornerstone investors subscribed to 34.71%, including well-known institutions like OrbiMed Asia and Greater Bay Area Homeland Development Fund, with a lock-up period of 6 months.
Reasonable Valuation: Corresponds to a 2025 PE of about 34x. Considering the leader premium and high growth rate, the valuation is within a reasonable range.
Tianxing Medical is a core target for domestic substitution in sports medicine, combining four major advantages: a high-growth track, strong profitability, solid technological barriers, and small-cap scarcity. Driven by both centralized procurement benefits and overseas expansion, it has vast growth potential.
IPO Subscription Recommendation: Actively participate, prioritize Group B or the tail of Group A. It can be a core holding in the medical device sector for the long term.
Tianxing Medical (01609) VS Aikang Medical, Weigao Orthopedics Core Comparison
Focusing on valuation, gross margin, growth rate, track, and the impact of centralized procurement, this comparison clearly shows Tianxing's advantages, aiding decision-making for Hong Kong stock IPOs.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
